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Adhesion molecules and rejection of renal allografts. Despite an
increasing amount of immunohistochemical and molecular biology data
relating to the pathogenesis of kidney transplant rejection, the patholog-
ical diagnosis of this condition still rests on routine light microscopy. The
detection of changes in expression and distribution of adhesion molecules
in renal allograft biopsies may open a new era of increased accuracy of
rejection diagnosis. Of the various adhesion molecule reactivities, peritu-
bular capillary VCAM-1 staining appears to be the most specific finding
for chronic rejection. This same staining reaction is seen in acute rejection,
but may have less specificity in that setting.
There has been substantial progress recently in the understand-
ing of adhesion molecules and their complex interactions in
human disease [1, 2]. The involvement of these molecules in the
rejection of transplanted organs has been an area of special
interest [3, 4].
The transplanted kidney is an ideal natural laboratory for the
study of involvement of adhesion molecules in renal diseases.
Repeat biopsies are frequently performed throughout the course
of the transplant, and these may identify recurrent disease at an
earlier time than it would be possible to observe the same process
in the native kidney. In addition, diseases may progress more
quickly in a single tranplanted kidney than they would in native
kidneys, thus allowing the identification of more stages of the
disease in a shorter time period. Focal glomerulosclerosis, a
condition that may recur within minutes in the transplanted
kidney, is one disease that has been studied in this manner [5].
Kemeny et al [5] found that podocytes show altered integrin
distribution in idiopathic focal glomerular sclerosis that changes
in the course of the disease. They postulated that podocytes lose
their adhesive phenotype in early FSGS, which may contribute to
the detachment of podocytes from the GBM.
Studies on involvement of adhesion molecules in ischemia-
reperfusion injury [6] are particularly relevant to the transplanted
kidney, where ischemic injury leads to shedding of live tubular
cells into the urine which is an order of magnitude greater than
that observed in the ischemically-damaged native kidney [7].
Probably the most interesting area of investigation in which
adhesion molecules have been studied in the transplanted kidney
is in acute and chronic rejection [8—12]. This communication will
briefly review the functional significance and the diagnostic and
therapeutic utility of adhesion molecule expression in acute and
chronic renal transplant rejection.
Acute rejection
Acute rejection of renal allografts involves many interrelated
processes, including recognition of alloantigens, activation and
proliferation of allospecific T cells, recruitment, interaction, and
migration of effector inflammatory cells, all resulting in target cell
damage by cytolytic or delayed hypersensitivity mechanisms.
Recently, it has become increasingly apparent that various adhe-
sion molecules play pivotal roles in these processes [13—181.
Indeed, treatment with antibodies against several adhesion mol-
ecules can reverse or even prevent acute rejection in animal
models and clinical studies [14, 18—21].
Functional significance of adhesion molecules in acute allograft
rejection
The adhesion molecules mediating various processes in acute
rejection and their ligands are summarized in Tables 1 to 5. It
should be noted that many adhesion molecules are expressed by
several cell types and thus may mediate more than one function
[13—18]. Although numerous synonyms exist for some adhesion
molecules, only the most recent and widely accepted names and
abbreviations are used herein [13—18, 22].
Antigen presentation
It is well known that specific recognition of the alloantigen-
MHC complex on antigen presenting cells by the T cell receptor-
CD4 (or CD8) complex results in activation of T lymphocytes only
if secondary stimulatory signals are provided by additional con-
tacts between antigen presenting cells and T cells [13, 23]. This
accessory stimulatory contact is provided by the pairs of adhesion
molecules listed in Table 1 [13—18]. Aside from the dendritic
reticulum cells ("professional" antigen presenting cells), any cell
with constitutive or induced expression of MHC molecules may
assume this function. However, whether the antigen presentation
results in activation of allospecific T-cells depends on whether
antigen presenting cells express the appropriate adhesion mole-
cules for secondary signaling [23].
Inflammatory cell-endothelial cell interactions
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During acute rejection, inflammatory cells, including T lympho-
cytes, must come in contact with endothelial cells, which not only
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Table 1. Adhesion molecules and antigen presentation
T cells
Antigen presenting
cells
LFA-1 ICAM
VLA-4 VCAM-1
CD28 B7 and B70
CTLA-4 B7 and B70
LFA-2 LFA-2
Modified from Truong et al [121.
Table 2. Adhesion molecules and endothelial-inflammatory cell
interaction
Inflammatory cells Endothelial cells
Glycoproteins and glycolipids E-selectin
Glycoproteins and glycolipids P-selectin
PECAM-1 PECAM-1
L-selectin GIyCAM-1
CD44 Hyaluronate
VLA-4 VCAM-1
LFA-1 ICAM-1
LFA-2 LFA-3
Modified from Truong et al [121.
Table 3. Adhesion molecules and transendothelial migration of
inflammatory cells
Inflammatory cells Endothelial cells
LFA-1 ICAM-1
VLA-4 VCAM-1
Modified from Truong et al [121.
present alloantigens and are, themselves, targets for immune-
mediated injury, but also constitute a barrier through which
inflammatory cells must transmigrate in order to localize in the
renal interstitium [13—18]. The necessary contact is mediated by
the pairs of adhesion molecules listed in Table 2. Interactions of
VLA-4/VCAM-1 and LFA-1/ICAM-1 are of indisputable impor-
tance in acute rejection and have been thoroughly evaluated in the
tissue diagnosis of rejection [24—26]. Although other adhesion!
ligand pairs play crucial roles in inflammation, whether they
facilitate acute rejection or whether their identification in tissue
sections has a diagnostic role remains unclear [13—18, 23—261.
Transendothelial migration of inflammatory cells
Allospecific or non-specific inflammatory cells must migrate
through capillaries to infiltrate the interstitium, an important
feature of acute cellular rejection. This highly complex process
likely depends on the interplay of many factors, including cyto-
kines, chemotactic factors, and adhesion molecules [27, 28]. The
role of specific adhesion molecules in this process has been partly
elucidated [13, 27, 28]. LFA-1!ICAM-1 interaction appears crucial
to this process Table 3, as T cell clones from LFA-1 deficient
individuals bind normally to cultured endothelial monolayers, but
migrate through cultured eridothelial cells at only about half the
rate of normal lymphocytes [29]. In addition, monoclonal anti-
bodies against LFA-1 markedly reduce lymphocyte migration [30].
Recently, transendothelial migration of human monocytes has
been shown to be mediated by VLA-4 [31].
Table 4. Adhesion molecules and interstitial localization of
inflammatory cells
Inflammatory cells
Interstitial cells,
extracellular matrix
LFA-1 ICAM-l (on interstitial fibroblasts)
VLA-4 Receptors on extracellular matrix
VLA-1 to VLA-6 Receptors on extracellular matrix
CD44 Hyaluronate
Modified from Truong et al [121.
Table 5. Adhesion molecules and mediation of binding of cytotoxic
T cells or natural killer cells to target cells
Inflammatory cells Target cells
VLA-4 (activated T cells) VCAM-1 (activated tubular and
endothelial cells)
CD44 (lymphocytes) Hyaluronate (on target cells?)
LEA-i (leukocytes, natural ICAM-l (activated tubular and
killer cells) endothelial cells)
Mac-i (macrophages, granulocytes, ICAM-1 (activated tubular and
natural killer cells) endothelial cells)
LFA-2 (T cells, natural killer cells) LFA-3 (tubular and endothelial
cells)
Modified from Truong et al [121.
Interstitial localization of inflammatory cells
The dynamics of inflammatory cells in the renal interstitium are
poorly understood (Table 4). The role of adhesion molecules in
interstitial inflammation is mostly conjectural, based on knowl-
edge of adhesion molecules expressed by inflammatory cells and
their ligands found on fibroblasts and extracellular matrix pro-
teins. For example, LFA-1 on T-lymphocytes can bind to ICAM-.1
induced on interstitial fibroblast-like cells during rejection. VLA-4
and VLA-5 on activated T cells can bind fibronectin, and VLA-1,
VLA-2, VLA-3, VLA-5, and VLA-6 may bind various other
extracellular matrix proteins, including collagens and laminin [22].
Binding of cytotoxic T-cells and natural killer cells to target cells
Effector cells mediate damage to the rejected kidney through
many mechanisms, one of which is lysis of target cells by CD8 + T
lymphocytes or natural killer cells. Cell to cell contact, which may
be provided by the pairs of adhesion molecules listed in Table 5,
is necessary for these cells to deliver the "cytolytic hit" [32]. These
specific adhesion molecule interactions may explain, at least in
part, the attachment of CD8 T cells to activated endothelial cells
in producing endothelialitis and the infiltration of these lympho-
cytes between tubular epithelial cells with resultant tubulitis. Both
endothelialitis and tubulitis are characteristically seen in acute
rejection [33].
Several studies have reported prevention or reversal of acute
rejection in animals or humans by treatment with antibodies
against various adhesion molecules, including ICAM-1 and
LFA-1, These fascinating observations confirm the crucial role of
adhesion molecules in the diverse biological processes leading to
acute rejection [18—21].
1478 Solez Ct al: Transplant rejection and adhesion molecules
Modified from Truong et a! [121.
Table 6. Staining patterns for adhesion molecules in normal and rejecting kidney
ICAM-1 VCAM-1 E-se!ectin P-selectin PECAM-1
Norma! Rejection Norma! Rejection Norma! Rejection Norma! Rejection Normal Rejection
+ + ± ± + +
+ +
± ++
± ++ ± ± ± ± ±
+ + ± + ± ± ± + +
Diagnostic utility of adhesion molecule expression in acute
renal allograft rejection
Although numerous adhesion molecules are implicated in acute
rejection, only a few of them have been evaluated for diagnostic
use. Most thoroughly studied are ICAM-1 and VCAM-1, whereas
significantly less information is available for E-selectin, P-se!ectin,
and PECAM-1. The diagnostic use of these molecules centers
around their immunohistochemical detection in graft biopsies.
Rare studies have supplemented immuriohistochemical analysis
with in situ hybridization [24, 34]. Studies analyzing the corre-
sponding mRNAs by Northern hybridization or polymerase chain
reaction have not been attempted and likely would not have the
same diagnostic utility since changes in message level would not
be site specific. As implied above, some adhesion molecules are
expressed by multiple cell types (such as ICAM-1 on monocytes,
mesangial cells, lymphocytes, endothelial cells, tubular epithelial
cells), some of which may have up-regulated expression in disease
processes other than rejection, which can affect the transplanted
kidney. It is the change in expression of these molecules at specific
renal compartments that provide the diagnostic clues. This infor-
mation is best provided by immunohistochemistry. Staining pat-
terns with monoclonal antibodies to the various pertinent adhe-
sion molecules in the normal kidney and renal allograft with
rejection are outlined in Table 6.
ICAM-1
All studies agree that ICAM-1 is strongly expressed constitu-
tively in endothelial cells of the normal kidney, and is not
phenotypically altered during acute rejection [24—26, 35—401. In
contrast, the normal tubules are either completely negative or
display weak staining of rare proximal tubules in up to 65% of
cases. Acute rejection is associated with diffuse staining of prox-
imal tubules, predominantly the brush border, and focal staining
of distal tubules and collecting ducts. The diagnostic utility of
ICAM-1 expression is somewhat lessened since biopsies of grafts
without rejection or grafts with stable function also sporadically
express increased tubular ICAM-1 [37, 38]. Nevertheless, staining
for ICAM-1 has been used for differentiating acute rejection from
cyclosporine A nephrotoxicity [41].
VcAM-1
The glomerular endothelial cells in normal kidney do not
express VCAM-1 and remain negative in acute rejection [34,
36—38, 42—45]. In contrast, the endothelial cells of peritubular
capillaries or large vessels display negative or very weak, focal
staining in normal kidney, but become strongly and diffusely
positive during acute rejection. The changes of tubular VCAM-1
expression in acute rejection are similar to that of ICAM-l except
that the staining is basolateral rather than !uminal (brush border).
Some preliminary reports indicate overlapping patterns of
VCAM-1 staining between rejecting and stable grafts [37, 38].
E-selectin
Expression of E-selectin is not seen in normal kidney, but is
observed focally in endothelium of peritubular capillaries and
large vessels during rejection [25, 26, 36—38].
P-selectin
P-selectin appears to be focally expressed in endothelial cells of
normal kidneys and is not detectably altered during acute rejec-
tion [38].
PECAM-1
Immunohistochemica! staining for this adhesion molecule
strongly decorates all endothelia! cells in normal kidney. During
acute rejection, up to 17% of cases paradoxically display focal
loss of staining, which may be related to endothelial damage [26].
Another preliminary study, however, indicated increased
PECAM-1 staining in acute rejection [25].
Current data on adhesion molecules in serum, as opposed to
tissue expression, are meager and, in general, indicate a lack of
diagnostic implication. Specifically, serum level of ICAM-1,
VCAM-1, and E-selectin was shown to correlate with serum
creatinc but not with diagnostic categories. Moreover, increased
serum VCAM-1 has been noted in CMV infection in renal
transplant recipients [16, 39, 40].
Adhesion molecules and their ligands in chronic rejection
Little work has been done thus far in this field. Duijvwestijn et
al [46] found increased expression of ICAM-1 and its ligands in a
subpopulation (7 of 52) of glomeruli in a rat model of chronic
rejection. They suggested that the positive glomeruli may play an
important role in the development of chronic rejection.
Hill, Main and Atkins [10] and von Willebrand et a! [47] found
that peritubular capillary VCAM-1 staining was the most specific
finding for chronic rejection in human kidneys. They postulate
that the up-regulation of VCAM-1 may be one of the important
etiologic factors in the development of chronic rejection.
VCAM-1 appears to be the most diagnostically relevant adhesion
molecule in chronic rejection.
Glomerular endothelial cells
Mesangia! cells
Podocytes
Paricta! epithelia! cells
Tubular cells
Peritubular capillary
endothelia! cells
Endothe!ial cells of larger vessels
+ +
± ++
+ +
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Conclusion
The study of adhesion molecules not only provides significant
insight into the mechanisms leading to acute and chronic renal
allograft rejection, but also opens new venues for therapeutic
manipulation. Although acute rejection is frequently associated
with distinctive changes in the tissue expression of several adhe-
sion molecules, the precise role of these changes in the differential
diagnosis of acute rejection awaits further studies.
Standard approaches to the diagnosis of acute and chronic
transplant rejection do not employ immunochemical or molecular
biology techniques [48, 49]. It is hoped that with further investi-
gation of adhesion molecules, their detection may begin a new
phase of increased accuracy of rejection diagnosis.
Reprint requests to Luan D. Truong, M.D., Department of Pathology, M.S.
205, The Methodist Hospital, Houston, Texas 77030, USA.
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